Transforming growth factor-β: A promising target for anti-stenosis therapy

Cardiovascular Drug Reviews

Volumn 19, Issue 4, 2001, Pages 329-344

  Chamberlain, J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

PTCA; Restenosis; Stent; TGF

Indexed keywords

ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CORONARY STENT; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; STENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; WOUND HEALING;

EID: 0035724807     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00074.x     Document Type: Review

References (149)

1. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members
2. Transforming growth factor-β1: Secondary structure as determined by heteronuclear magnetic resonance spectrometry
3. Smads as transcriptional co-modulators
4. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
5. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease
6. The recombinant proregion of transforming growth factor β1 (latency-associated peptide) inhibits active transforming growth factor in transgenic mice
7. Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics
8. Use of locally delivered conventional drug therapies
9. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats
10. TGF-β is active, and correlates with activators of TGF-β, following porcine coronary angioplasty
11. The effect of suramin on healing adult rodent dermal wounds
12. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors
13. Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon-injured rat carotid artery
14. Phosphorylation-dependent interaction of the cytoplasmic domains of the type I and type II transforming growth factor-β receptors
15. Control of scarring in adult wounds using antisense transforming growth faetor-β1 oligodeoxynucleotides
16. Thrombospondin-1 is a major activator of TGF-β1 in vivo
17. Dual role for the latent transforming growth factor-β binding-protein in storage of latent TGF-β in the extracellular-matrix and as a structural matrix protein
18. Crystal structure of transforming growth factor-β2: An unusual fold for the superfamily
19. 4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-β in cocultures with sinusoidal endothelial cells
20. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor
21. Smads: Transcriptional activators of TGF-β responses
22. TGF-β receptor signaling
23. Intron-exon structure of human transforming growth factor-β precursor gene
24. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells
25. The type II recptors for TGF-β or activin determine the ligand specificity of a single type I receptor
26. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor
27. Betaglycan inhibits TGF-β signaling by preventing type I/type II receptor complex formation
28. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporin A in lung fibroblasts
29. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation
30. Wound healing - Scar wars
31. Local expression of bovine decorin by cell-mediated gene transfer reduces neointimal formation after balloon injury in rats
32. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats
33. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1
34. Local Drug Delivery for Restenosis and Thrombosis Progress?
35. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
36. Is local drug delivery truly a low efficiency procedure?
37. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling
38. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods
39. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial
40. Feasibility and efficacy of locally delivered enoxaparin via the Channeled Balloon catheter on smooth muscle cell proliferation following balloon injury in rabbits
41. Localized drug delivery in atherosclerotic arteries via a new balloon angioplasty catheter with intramural channels for simultaneous local drug delivery
42. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery
43. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat
44. Smad6 inihibits signaling by the TGF-β superfamily
45. Interplay of signal mediators of decapentaplegic (Dpp): Molecular characterisation of mothers against dpp, Medea, and daughters against dpp
46. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
47. Differential inhibition of Smad6 and Smad7 on bone morphogenic protein- and activin-mediated growth arrest and apoptosis in B cells
48. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells
49. Signaling of transforming growth factor-β family members through Smad proteins
50. Transforming growth factor β1 induces nuclear export of inhibitory Smad7
51. Complementary deoxyribonucleic acid cloning of a novel transforming growth factor-β messenger ribonucleic acid from chick embryo chondrocytes
52. Nucleotide sequence of chicken transforming growth factor-β1 (TGF-β1)
53. Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF beta in the rabbit
54. Inactivation of menin, a Smad3-interacting protein blocks transforming growth factor type β signalling
55. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors
56. Sustained intramural retention and regional redistribution following local vascular delivery of polylactic-coglycolic acid and liposomal nanoparticulate formulations containing probucol
57. Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells
58. Latency, activation, and binding proteins of TGF-β
59. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist
60. Transforming growth factor beta (TGF-β) induces fibrosis in a fetal wound model
61. Partnership between DPCA and SMAD proteins in TGF-β signaling pathways
62. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin
63. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality
64. Roles of pathway-specific and inhibitory Smads in activin receptor signaling
65. Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans
66. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase
67. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model
68. Betaglycan presents ligand to the TGF-β signalling receptor
69. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in IGF2 and IGF1r null backgrounds
70. Transforming growth factor-β2: cDNA cloning and sequence analysis
71. Phosphorylcholine-coated stents in porcine coronary arteries: In vivo assessment of biocompatibility
72. Characterisation and regulation of the latent transforming growth factor-β complex secreted by vascular pericytes
73. Transcriptional control by the TGF-β/Smad signaling system
74. TGF-β signal transduction
75. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth
76. Catheter-based local thrombolysis with urokinase: Comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model
77. Local urokinase delivery with the Channel balloon: Device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis
78. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons
79. Latent high molecular weight complex of transforming growth factor-β1 - Purification from human platelets and structural characterization
80. The integrin αvβ6 binds and activates latent TGF β1: A mechanism for regulating pulmonary inflammation and fibrosis
81. Activation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology
82. Accelerated healing of incisional wounds in rats induced by transforming growth factor-β
83. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia
84. TGF-β receptor-mediated signaling through Smad2, Smad3 and Smad4
85. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signaling
86. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions
87. Latent transforming growth factor-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-β
88. Characterization of latent TGF-β activation by murine peritoneal macrophages
89. βig-h3, a transforming growth factor-β-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions
90. Purification and characterisation of transforming growth factor-beta 2.3 and -beta 1.2 heterodimers from bovine bone
91. 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process
92. Prevention of rat hepatic fibrosis by the protease inhibitor camostat mesilate, via reduced generation of active TGF-β
93. Transforming growth factor-β1, factor β2, and factor β3 secreted by a human glioblastoma cell line - Identification of small and different forms of large latent complexes
94. Specificity, diversity and regulation in TGF-β superfamily signaling
95. Transforming growth factor-β stimulates wound healing and modulates extracellular matrix gene expression in pig skin. I. Excisional wound model
96. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β
97. Transforming growth factor-β
98. The Transforming Growth factor-βs
99. Functional cloning of the proto-oncogene brain factor-1 (BF-1) as a Smad-binding antagonist of transforming growth factor-β signalling
100. Cooperative binding of transforming growth factor (TGF)-β2 to the types I and II TGF-β receptors
101. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia
102. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1
103. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism
104. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty
105. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months
106. Cartilage-inducing factor-A
107. Neutralisation of TGF-β2 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring
108. Neutralising antibody to TGF-β 1, 2 reduces cutaneous scarring in adult rodents
109. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β
110. Cloning and sequence analysis of simian transforming growth factor-β cDNA
111. Transforming growth factor-β1 expression and myofibroblast formation during arterial repair
112. Thrombospondin co-localises with TGF β and IGF-I in the extracellular matrix of human osteoblast-like cells and is modulated by 17 β estradiol
113. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth
114. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model
115. Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenic protein receptors and transforming growth factor-β receptors
116. Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-β1-induced cellular responses
117. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo
118. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells
119. Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein
120. Release of transforming growth factor-β1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin
121. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty trial (TREAT)
122. An anchor for activation
123. Effect of topical anti-transforming growth factor-beta on corneal stromal haze after photorefractive keratectomy in rabbits
124. Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery
125. SARA a FYVE domain protein that recruits Smad2 to the TGF-β receptor
126. Daughters against dpp modulates dpp organising activity in Drosophila wing development
127. Intramural injection of biodegradable microspheres as a local drug-delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty
128. Regulation of cell surface tissue transglutaminase: Effects on matrix storage of latent transforming growth factor-beta binding protein-1
129. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent
130. Pathology of in-stent restenosis
131. Latent transforming growth factor-β from human platelets - A high molecular weight complex containing precursor sequences
132. Regulation of embryonic growth and lysosomal targeting by the imprinted IGF2/Mpr gene
133. Accentuated neointimal formation after stenting is TGF-β dependent
134. Inhibitory effects of tranilast on expression of transforming growth factor-β isoforms and receptors in injured arteries
135. The extracellular matrix of lip wounds in fetal, neonatal and adult mice
136. Immunohistochemical localization of growth factors in fetal wound healing
137. Signal transduction. Feedback from inhibitory SMADs
138. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model
139. Mechanism of activation of the TGF-β receptor
140. TGF-β signals through a heteromeric protein kinase receptor complex
141. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4
142. Expression of transforming growth factor-β1 (TGF-β1) and urokinase-type plasminogen activator (u-PA) genes during arterial repair in the pig
143. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1
144. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation
145. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse
146. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall
147. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36
148. Adenovirns-mediated gene transfer of dominant-negative Smad4 blocks TGF-β signaling in pancreatic acinar cells